Cabrera Camila, Ogyaadu Selassie, Levister Camilla, Kaplan Leah, Ipek Aslihan, Ferrara Lauren, Levy Carol J, O'Malley Grenye
Maternal Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Science, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Division of Endocrinology, Diabetes and Bone Disease, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
J Diabetes Sci Technol. 2025 Jul 3:19322968251351819. doi: 10.1177/19322968251351819.
Up to one-third of people with gestational diabetes (GDM) will have persistent dysglycemia, and more than half do not complete the recommended postpartum oral glucose tolerance test (OGTT). This study assessed the use of blinded postpartum continuous glucose monitoring (CGM) to detect dysglycemia by assessing return rates, participant experience, and power to predict OGTT results.
Blinded CGM was placed on postpartum day 1 to 3 before discharge from the hospital and again at six weeks after pregnancy complicated by GDM and worn at home for up to 10 days. Participants mailed the CGM back and were encouraged to undergo standard of care six-week OGTT.
Fifty women (36 ± 6 years old; 40% non-Hispanic white, 24% non-Hispanic black, 22% Asian, 14% Hispanic; 34% Medicaid insured) were consented. First CGM was completed by 86%, second CGM was completed by 60%, and postpartum OGTT was performed by 68%. Mean first sensor glucose was 121.8 ± 14.1 mg/dL. Dysglycemia on OGTT was diagnosed in seven participants: six with impaired glucose tolerance (18%) and one with diabetes (3%). Percent time <96% in the range 70 to 180 mg/dL predicted abnormal OGTT with positive predictive value of 54% and negative predictive value of 100%. The sensitivity and specificity of CGM to predict postpartum dysglycemia were 100% and 78%, respectively. If given a choice, 94% of participants would prefer CGM over OGTT.
Postpartum CGM is a reasonable and convenient initial postpartum screen for postpartum dysglycemia with high completion rates, sensitivity, and acceptability ratings. Percent time in range 70 to 180 mg/dL had strong predictive power for OGTT.
高达三分之一的妊娠期糖尿病(GDM)患者会出现持续性血糖异常,超过一半的患者未完成推荐的产后口服葡萄糖耐量试验(OGTT)。本研究通过评估回收率、参与者体验以及预测OGTT结果的能力,来评估使用盲法产后连续血糖监测(CGM)检测血糖异常的情况。
在产后第1至3天出院前以及妊娠合并GDM后的六周再次进行盲法CGM,在家佩戴长达10天。参与者将CGM邮寄回来,并被鼓励接受标准的六周OGTT检查。
50名女性(36±6岁;40%为非西班牙裔白人,24%为非西班牙裔黑人,22%为亚洲人,14%为西班牙裔;34%有医疗补助保险)同意参与。86%的人完成了首次CGM,60%的人完成了第二次CGM,68%的人进行了产后OGTT。首次传感器测得的平均血糖为121.8±14.1mg/dL。7名参与者的OGTT诊断为血糖异常:6名糖耐量受损(18%),1名糖尿病(3%)。在70至180mg/dL范围内低于96%的时间百分比预测OGTT异常的阳性预测值为54%,阴性预测值为100%。CGM预测产后血糖异常的敏感性和特异性分别为100%和78%。如果可以选择,94%的参与者更喜欢CGM而非OGTT。
产后CGM是一种合理且方便的产后血糖异常初始筛查方法,具有较高的完成率、敏感性和可接受性评分。70至180mg/dL范围内的时间百分比对OGTT具有很强的预测能力。